|

HRS-6209 Clinical Trials

2 actively recruiting trials

▲ +1 trial since May 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Shandong Suncadia Medicine Co., Ltd.1
  • Fudan University1

Indications

  • Breast Cancer2
  • Cancer2
  • Hormone Receptor Negative Tumor1
  • Advanced Unresectable or Metastatic Breast Cancer1
  • Hormone Receptor Positive Tumor1

Other2 trials

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
Phase 1/2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.